Table 8.
Application of circulating miRNAs in specific treatment of multiple myeloma.
| Author | miRNA | Sample size | Treatment | Outcome |
|---|---|---|---|---|
| Jiang Y (17) | miR-125b-5p | Total: 35 | Bortezomib, thalidomide, and dexamethasone, followed by thalidomide Maintenance | EFS: High, 8 months; low, 13 months, p=0.02 |
| miR-490-3p | Total: 35 | EFS: High, 12 months; low, 13 months, p=0.23 | ||
| Hao M. (22) | miR-19a | High level: 23 Low level: 30 | Bortezomib-based | Patients with low miR-19a had significantly extended PFS (NR vs. 10.0 months), p=0.002 |
| miR-19a | High level: 28 Low level: 22 | Thalidomide-based | Non-significance | |
| Ren Y (63) | miR-720 + miR-1246 | Decreased:28 Increased: 8 | Bortezomib plus low-dose dexamethasone | Elevated levels were associated with worse PFS (p=0.0277) |
| Decreased:16 Increased: 8 | Vincristine, adriamycin, and dexamethasone | Elevated levels were associated with worse PFS (p=0.0184) | ||
| Robak P (65) | miR-744-5p | Refractory group: 19 Sensitive group:11 | Bortezomib-based | Distribution difference, p=0.0006; predict refractoriness: OR=0.06, p=0.0146 |
| miR-143-5p | Distribution difference, p=0.0051; predict refractoriness: OR=4.14, p=0.0157 | |||
| Narita D (66) | mir-92a | Newly diagnosed: 10; relapsed and/or refractory: 52 | Bortezomib plus low-dose dexamethasone | Had higher expression in relapsed and/or refractory MM than in newly diagnosed MM, and correlated with chemotherapy response and disease progression |
| Yoshizawa S (67) | miR-92a | Total: 138 | Bortezomib | Only up-regulated after therapy in responders |
| Hao M (68) | miR-214 | Total: 108 | Bisphosphonates | Higher level corelated with extended OS (NR vs 26.0 months, p=0.029) |
| Nowicki M (69) | miR-15a | Total: 42 | Autologous hematopoietic stem cell transplantation | Patients with low expression on day 0 had a shorter time to engraftment than those with high expression (11 vs 13 days), p=0.01 |
| Navarro A (70) | miR-20a | Total: 33 | Autologous stem cell transplant | Expression at diagnosis was lower than complete remission, p= 0.009 |
| Jung SH (71) | miR-19a | Good/poor responders: 19/19 | Lenalidomide plus low-dose dexamethasone | Expressed between good responders and poor responders, p=0.073 |
| miR-20a | Between good responders and poor responders, p=0.241 | |||
| Jasielec JK (72) | miR-199 | Total: 30 | Carfilzomib, lenalidomide, and dexamethasone | PFS: with decreased risk for progression, HR=0.41; p=0.04 |
| Manier S (73) | let-7e | Total: 156 | Bortezomib plus low-dose dexamethasone, followed by high-dose melphalan and autologous stem cell transplant | Low level, PFS: HR 2.01 (95%CI, 1.30-3.11), p=0.002; OS: HR 2.39 (95%CI, 1.09-5.24), p=0.030 |
| miR-125b | Low level, PFS: HR 1.02 (95%CI, 0.70-1.49), p=0.906; OS: HR 1.27 (95%CI, 0.60-2.72), p=0.533 | |||
| miR-15a | Low level, PFS: HR 1.37 (95%CI, 0.94-2.00), p=0.101; OS: HR 2.27 (95%CI, 1.02-5.06), p=0.046 | |||
| miR-19a | Low level, PFS: HR 0.13 (95%CI, 0.02-0.99), p=0.049 | |||
| miR-20a | Low level, PFS: HR 2.31 (95%CI, 1.52-3.53), p<0.001; OS: HR 2.91 (95%CI, 1.29-6.54), p=0.010 | |||
| miR-744 | Low level, PFS: HR 1.32 (95%CI, 0.91-1.93), p=0.144; OS: HR 2.10 (95%CI, 0.97-4.53), p=0.059 | |||
| miR-92a | Low level, PFS: HR 1.39 (95%CI, 0.95-2.02), p=0.089; OS: HR 2.15 (95%CI, 1.00-4.65), p=0.051 |
CI, confidence interval; HR, hazard ratio; MM, multiple myeloma; NR: not reached; OR, odds ratio; OS, overall survival; PFS, progression-free survival.